Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SYMPHONY ND-Long: Long-term Safety and Efficacy of JTZ-951 (enarodustat) in Non-dialysis CKD Anemia
jRCT2080223643Phase 3Completed
- Sponsor
- Japan Tobacco
- Start
- Sep 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of enarodustat in anaemia (2 arms), sponsored by Japan Tobacco. Primary endpoint: Long-term safety of enarodustat over 52 weeks. Started Sep 2017; status: completed.
02
Drugs
enarodustat
03
Conditions
anaemia
Beyond the preview
Go deeper on jRCT2080223643.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223643.